AWS seeks to boost its AI products' organic growth, while rivals such as Cursor and Windsurf see better grassroots adoption.
Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could have a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback